Similar articles

• The Food and Drug Administration's regulation of risk disclosure for implantable cardioverter defibrillators: has technology outpaced the Agency's regulatory framework?

  Basile EM, Lorell BH. Basile EM, et al. Food Drug Law J. 2006;61(2):251-72. Food Drug Law J. 2006. PMID: 16903031 No abstract available.
• The controversy over Guidant's implantable defibrillators.

  Steinbrook R. Steinbrook R. N Engl J Med. 2005 Jul 21;353(3):221-4. doi: 10.1056/NEJMp058158. N Engl J Med. 2005. PMID: 16034006 No abstract available.
• Life-threatening malfunction of implantable cardiac devices.

  Myerburg RJ, Feigal DW Jr, Lindsay BD. Myerburg RJ, et al. N Engl J Med. 2006 Jun 1;354(22):2309-11. doi: 10.1056/NEJMp068112. Epub 2006 May 15. N Engl J Med. 2006. PMID: 16702187 No abstract available.
• Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.

  Kesselheim AS, Mello MM. Kesselheim AS, et al. Health Aff (Millwood). 2007 Mar-Apr;26(2):483-91. doi: 10.1377/hlthaff.26.2.483. Health Aff (Millwood). 2007. PMID: 17339677 Review.
• The year in clinical electrophysiology.

  Scheinman MM, Keung E. Scheinman MM, et al. J Am Coll Cardiol. 2006 Mar 21;47(6):1207-13. doi: 10.1016/j.jacc.2005.12.043. Epub 2006 Feb 28. J Am Coll Cardiol. 2006. PMID: 16545653 Review. No abstract available.